Search

Your search keyword '"Leighl, N."' showing total 184 results

Search Constraints

Start Over You searched for: Author "Leighl, N." Remove constraint Author: "Leighl, N." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
184 results on '"Leighl, N."'

Search Results

1. Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

3. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy

4. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

5. EP12.03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)

6. Survival Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated with Consolidative Thoracic Radiotherapy at a Tertiary Cancer Center

10. 27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe

11. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure

15. EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

16. 1151P Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT)

17. 1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations

19. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer

23. EP08.02-173 Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

24. EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC

25. 1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)

27. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study

28. EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

30. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)

32. EP03.01-002 Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations

35. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

36. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

37. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

38. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

39. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

40. FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients

41. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival

42. OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population

43. P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients

44. P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada

45. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC

47. FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907

48. P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

50. P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC

Catalog

Books, media, physical & digital resources